Wu Mei-Yun, Kuo Sheng-Chih, Chuang Su-Fen, Yeh Cheng-Hsi, Yin Shih-Min, Li Wei-Feng, Wang Hung-Jen, Chen Chao-Long, Wang Chih-Chi, Lin Chih-Che
College of Nursing, Kaohsiung Medical University, Kaohsiung, Taiwan.
Department of Nursing, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Ann Med Surg (Lond). 2021 Feb 18;63:102094. doi: 10.1016/j.amsu.2021.01.042. eCollection 2021 Mar.
Liver transplantation (LT) is one of the widely recognised and leading treatments for end-stage liver disease. Nutrition impacts its success. Total parenteral nutrition (TPN) is usually prescribed for patients recommended prolonged fasting after LT. The supplement of SMOFlipid (soybean oil, MCT oil, olive oil, and fish oil) is easily metabolised to produce energy, and it possesses anti-inflammatory effects; however, SMOFlipid emulsion use raises concerns regarding coagulopathy after LT. This study investigated the postoperative correlation between SMOFlipid and coagulation in LT.
The medical records of 54 recipients of living donor LT between January 2012 and June 2015 were retrospectively reviewed. Patients with pretransplant platelet count <40,000/μL and >40,000/μL were assigned to the non-SMOFlipid (n = 23) group and the SMOFlipid (n = 31) group, respectively.
The coagulation and nutrition profile of patients improved significantly after TPN support. No significant difference was observed in the coagulation profile between SMOFlipid and non-SMOFlipid groups. Although the SMOFlipid group exhibited a higher platelet count than the non-SMOFlipid group on day 7 (P < 0.001), no significant differences were observed in the platelet count on 14 and 30 days after TPN support between the 2 groups.
TPN using SMOFlipid after LT is a good strategy for improving nutritional status without increasing the risks of bleeding and coagulation in patients intolerant of early enteral nutrition. Moreover, SMOFlipid use may not cause coagulopathy up to 14 days after LT. Overall, SMOFlipid provides nutritional benefits without increasing the risk of bleeding.
肝移植(LT)是终末期肝病广泛认可的主要治疗方法之一。营养状况会影响其治疗效果。对于肝移植后建议长时间禁食的患者,通常会采用全胃肠外营养(TPN)。SMOFlipid(大豆油、中链甘油三酯油、橄榄油和鱼油)补充剂易于代谢产生能量,且具有抗炎作用;然而,使用SMOFlipid乳剂会引发对肝移植后凝血障碍的担忧。本研究调查了肝移植中SMOFlipid与凝血之间的术后相关性。
回顾性分析2012年1月至2015年6月期间54例活体肝移植受者的病历。移植前血小板计数<40,000/μL和>40,000/μL的患者分别被分配至非SMOFlipid组(n = 23)和SMOFlipid组(n = 31)。
TPN支持后患者的凝血和营养状况显著改善。SMOFlipid组和非SMOFlipid组之间的凝血状况未观察到显著差异。尽管SMOFlipid组在第7天时血小板计数高于非SMOFlipid组(P < 0.001),但两组在TPN支持后14天和30天的血小板计数未观察到显著差异。
肝移植后使用含SMOFlipid的TPN是改善不耐受早期肠内营养患者营养状况的良好策略,且不会增加出血和凝血风险。此外,使用SMOFlipid在肝移植后14天内可能不会导致凝血障碍。总体而言,SMOFlipid在不增加出血风险的情况下提供了营养益处。